Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Brodowicz, T; Krzakowski, M; Zwitter, M; Tzekova, V; Ramlau, R; Ghilezan, N; Ciuleanuf, T; Cucevic, B; Gyurkovits, K; Ulsperger, E; Jassem, J; Grgic, M; Pinar, S; Szilasi, M; Wiltschke, C; Wagnerova, M; Oskina, N; Soldatenkova, V; Zielinski, C; Wenczl, M

doi:10.1016/j.lungcan.2006.01.006

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

Atıf İçin Kopyala

Brodowicz T., Krzakowski M., Zwitter M., Tzekova V., Ramlau R., Ghilezan N., ...Daha Fazla

LUNG CANCER, cilt.52, ss.155-163, 2006 (SCI İndekslerine Giren Dergi)

Cilt numarası: 52 Konu: 2
Basım Tarihi: 2006
Doi Numarası: 10.1016/j.lungcan.2006.01.006
Dergi Adı: LUNG CANCER
Sayfa Sayıları: ss.155-163

Özet

Purpose: The primary objective of this randomized phase III study was to show significant difference in median time to progression (TTP) in patients with advanced NSCLC treated with single-agent gemcitabine maintenance therapy versus best supportive care following gemcitabine plus cisplatin initial first-line therapy.